CRESTOR ROSUVASTATIN 10MG 30TABS

Description

CRESTOR® should be used as a supplement to the diet, when the response to diet and exercise is not sufficient.

Prevention of cardiovascular events: CRESTOR® is indicated in adult patients with an increased risk of atherosclerotic cardiovascular disease based on the presence of cardiovascular disease risk markers, such as elevated level of CRPas, age, arterial hypertension, low level of C- HDL, smoking, or a family history of premature coronary artery disease. CRESTOR® is indicated to reduce total mortality and the risk of major cardiovascular events (cardiovascular death, stroke, myocardial infarction, unstable angina or arterial revascularization).

In adult patients with hypercholesterolemia:

CRESTOR® reduces LDL-Cholesterol (LDL-C), total cholesterol and high triglycerides and increases HDL-Cholesterol
(HDL-C), in patients with primary hypercholesterolaemia (heterozygous familial and non-familial) and mixed dyslipidemia (including Fredrickson Type IIa and IIb). CRESTOR® also reduces: ApoB, Non-HDL-Cholesterol, VLDL-Cholesterol, VLDL-TG, as well as LDL-C / HDL-C, Total Cholesterol / HDL-C, Non-HDL-C / HDL-C, ApoB / ApoA -I and increases ApoA-I in these populations.

CRESTOR® is indicated in patients with primary dysbetalipoproteinemia (Fredrickson Type III hyperlipoproteinemia).

CRESTOR® is indicated for the treatment of isolated hypertriglyceridaemia (Fredrickson Type IV hyperlipidaemia).

CRESTOR® reduces total cholesterol and LDL-C in patients with homozygous familial hypercholesterolemia, either alone or as an adjunct to diet and other lipid-lowering treatments (eg, LDL apheresis).

CRESTOR® slows or reduces the progression of atherosclerosis.

Children and adolescents 10 to 17 years of age: CRESTOR® is indicated to reduce total cholesterol, LDL-C and Apo B in patients with heterozygous familial hypercholesterolemia (HeFH).